In 2004, a 68-year-old man received aortocoronary bypass surgery and a 23-mm Hancock porcine bioprosthesis (Medtronic, Minneapolis, Minnesota). Six years later, in January 2011, cardiac re-evaluation was performed due to progressive dyspnea. Invasive angiography showed open bypass grafts and severe stenosis of the porcine aortic bioprosthesis. Due to significant comorbidities, a 23-mm Sapien XT (Edwards Lifesciences, Irvine, California) transcatheter aortic valve (TAVI) was implanted as valve-in-valve. The procedure was uneventful. Initial angiography and echocardiography showed a good function of the valve with no insufficiency and a mean gradient of 20 mm Hg (Online Video 1).
In March 2011, 3 months after the procedure, the patient was readmitted with cardiac decompensation. Reangiography showed open bypass grafts, but an invasive gradient of 50 mm Hg over the Sapien valve. Echocardiography confirmed the severe stenosis of the Sapien valve with a maximum gradient of 66 mm Hg, a mean of 43 mm Hg, and a valve opening area of 0.6 cm 2 . Due to the severe dyspnea, reoperation was scheduled after recompensation. In May 2011, both the Sapien valve and the 2004 implanted Hancock bioprosthesis was explanted (Fig. 1 ) and replaced with a 21-mm Trifecta (St. Jude Medical, Inc., St. Paul, Minnesota) bioprosthesis. The post-operative course was uneventful.
Post-explantation assessment of the valves showed the implanted 23-mm Sapien valve incompletely expanded within the stents of the 23-mm Hancock bioprosthesis. This leads to asymmetrical commissural distances and wrinkles of the leaflets (Fig. 2) . In vitro investigation of the valves under pulsatile conditions showed folding and uneven leaflet coaptation in the diastolic state and a severely limited opening of the valve in systole, with a visual orifice area of 0.54 cm 2 (Online Video 2). Pressure gradients were 24.2 mm Hg (mean) and 42.2 mm Hg (maximum) at a cardiac output of 4.3 l/min.
Even though TAVI shows promising results in high-risk patients (1), the concept of valvein-valve in degenerated aortic bioprostheses is quite new (2) . Reports successfully demonstrated the feasibility of this approach (3). However, experimental studies could show the rigidity of the bioprosthesis can constrain the TAVI valve 
